MRKR - Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today? | Benzinga
Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter APOLLO clinical trial.
The APOLLO trial is investigating the safety and efficacy of MT-601 for patients with lymphoma who have either failed or are ineligible to receive anti-CD19 CAR T cell therapy.
This first APOLLO study participant ...